Q4 2021 |
144 |
$163M |
+$11.6M |
-$12.4M |
-$825K |
AAPL, MDB, RLAY, TPL, SPY
|
13F-HR |
2/2/2022, 12:24 PM |
Q3 2021 |
162 |
$153M |
+$22.3M |
-$5.72M |
+$16.6M |
AAPL, MDB, RLAY, TPL, SPY
|
13F-HR |
11/8/2021, 04:36 PM |
Q2 2021 |
158 |
$146M |
+$8.85M |
-$27.1M |
-$18.2M |
RLAY, AAPL, TPL, AMZN, BBIO
|
13F-HR |
8/11/2021, 03:17 PM |
Q1 2021 |
208 |
$155M |
+$11.5M |
-$16.9M |
-$5.39M |
TPL, RLAY, AAPL, GBT, BBIO
|
13F-HR |
5/6/2021, 12:22 PM |
Q4 2020 |
255 |
$153M |
+$26.6M |
-$15.2M |
+$11.4M |
AAPL, RLAY, GBT, BBIO, AMZN
|
13F-HR |
2/10/2021, 11:58 AM |
Q3 2020 |
239 |
$127M |
+$23.6M |
-$16.5M |
+$7.13M |
RLAY, GBT, AAPL, SAFT, AMZN
|
13F-HR |
11/12/2020, 04:16 PM |
Q2 2020 |
215 |
$111M |
+$13.7M |
-$24.6M |
-$10.9M |
GBT, SAFT, AMZN, SPY, BBIO
|
13F-HR |
8/13/2020, 09:59 AM |
Q1 2020 |
181 |
$102M |
+$19.2M |
-$11.3M |
+$7.87M |
GBT, SAFT, SPY, AMZN, MYOK
|
13F-HR |
5/12/2020, 12:27 PM |
Q4 2019 |
193 |
$121M |
+$26.2M |
-$19.4M |
+$6.79M |
GBT, SAFT, PTLA, MYOK, TPL
|
13F-HR |
2/13/2020, 01:34 PM |
Q3 2019 |
137 |
$98M |
+$8.45M |
-$119M |
-$110M |
GBT, PTLA, MYOK, IVV, TPL
|
13F-HR |
11/15/2019, 03:47 PM |
Q2 2019 |
180 |
$209M |
+$14.9M |
-$65.4M |
-$50.6M |
GBT, PTLA, AAPL, MSFT, MYOK
|
13F-HR |
8/14/2019, 04:07 PM |
Q1 2019 |
201 |
$255M |
+$58.5M |
-$44.1M |
+$14.4M |
GBT, PTLA, AAPL, MSFT, JPM
|
13F-HR |
5/15/2019, 04:18 PM |
Q4 2018 |
212 |
$215M |
+$54.3M |
-$54.9M |
-$590K |
MSFT, PFE, MYOK, PTLA, AAPL
|
13F-HR |
2/15/2019, 12:06 PM |
Q3 2018 |
208 |
$250M |
+$17.5M |
-$42.7M |
-$25.3M |
GBT, AAPL, MSFT, MYOK, IWM
|
Restatement |
11/14/2018, 03:05 PM |
Q2 2018 |
220 |
$246M |
+$127M |
-$69.1M |
+$58M |
MYOK, AAPL, MSFT, IWM, JPM
|
13F-HR |
8/14/2018, 07:44 PM |
Q1 2018 |
88 |
$188M |
+$26.6M |
-$111M |
-$84.4M |
BAC, JPM, MSFT, AAPL, STI
|
Restatement |
9/5/2018, 04:39 PM |
Q4 2017 |
80 |
$284M |
+$51.5M |
-$53.8M |
-$2.33M |
MSFT, AAPL, JPM, BAC, C
|
13F-HR |
2/12/2018, 04:37 PM |
Q3 2017 |
87 |
$275M |
+$57.7M |
-$38.1M |
+$19.6M |
AAPL, MSFT, JPM, CHKP, META
|
13F-HR |
11/13/2017, 11:26 AM |
Q2 2017 |
94 |
$250M |
+$20.2M |
-$15.1M |
+$5.1M |
AAPL, MSFT, EPD, JPM, TCP
|
13F-HR |
8/11/2017, 09:48 AM |
Q1 2017 |
89 |
$243M |
+$45.1M |
-$30.3M |
+$14.8M |
AAPL, MSFT, TCP, EPD, JPM
|
13F-HR |
5/2/2017, 04:36 PM |
Q4 2016 |
78 |
$220M |
+$33.9M |
-$36.9M |
-$2.95M |
MSFT, EPD, TCP, JPM, AAPL
|
13F-HR |
1/17/2017, 02:18 PM |
Q3 2016 |
77 |
$229M |
+$28.5M |
-$34M |
-$5.56M |
EPD, BGS, MSFT, HP, TCP
|
13F-HR |
10/4/2016, 11:39 AM |
Q2 2016 |
75 |
$238M |
+$22.4M |
-$19.5M |
+$2.91M |
EPD, SPH, APU, HP, BGS
|
13F-HR |
7/8/2016, 09:54 AM |
Q1 2016 |
83 |
$223M |
+$20M |
-$15.9M |
+$4.14M |
OMC, APU, FI, MCHP, AAPL
|
13F-HR |
4/7/2016, 10:51 AM |
Q4 2015 |
89 |
$210M |
+$46.5M |
-$55.3M |
-$8.82M |
OMC, MCHP, FI, AAPL, MSFT
|
13F-HR |
2/11/2016, 04:09 PM |
Q3 2015 |
107 |
$212M |
$0 |
$0 |
|
OMC, GSK, AAPL, AVY, MOH
|
13F-HR |
11/10/2015, 01:55 PM |
Q2 2015 |
107 |
$243M |
+$19.9M |
-$207M |
-$187M |
OMC, GSK, AAPL, AVY, MOH
|
13F-HR |
8/10/2015, 04:33 PM |
Q1 2015 |
98 |
$445M |
+$102M |
-$77.1M |
+$24.9M |
AAPL, MCHP, OMC, GSK, MOH
|
13F-HR |
5/11/2015, 01:51 PM |
Q4 2014 |
97 |
$416M |
+$80.8M |
-$19.2M |
+$61.6M |
KMI, TCP, NVS, FI, PH
|
Restatement |
2/18/2015, 11:11 AM |
Q3 2014 |
94 |
$352M |
+$24.6M |
-$26.3M |
-$1.66M |
TCP, EPD, NVS, BPL, FI
|
13F-HR |
10/15/2014, 09:08 AM |
Q2 2014 |
98 |
$364M |
+$264M |
-$97.2K |
+$264M |
EPD, BPL, GIS, OKS, NVS
|
13F-HR |
7/30/2014, 01:02 PM |
Q1 2014 |
81 |
$95.3M |
+$9.88M |
-$775K |
+$9.11M |
ADP, FI, BCR, PB, HRL
|
13F-HR |
4/29/2014, 09:37 AM |
Q4 2013 |
80 |
$86.5M |
$0 |
$0 |
|
ADP, FI, PH, PB, BCR
|
13F-HR |
1/21/2014, 03:33 PM |